Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

HUGE

FSD Pharma Inc

Jun 13 • 04:00PM ET

0.2151

Dollar change -0.0237
Percentage change -9.92	%

Healthcare • Drug Manufacturers - Specialty & Generic • Canada • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	14.35%	Shs Outstand	39.38M	Perf Week	-16.95%
Market Cap	8.70M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	0.00%	Shs Float	34.63M	Perf Month	-38.19%
Income	-10.18M	PEG	-	EPS next Q	-0.06	Inst Own	1.64%	Short Float	0.97%	Perf Quarter	-70.69%
Sales	0.00M	P/S	-	EPS this Y	52.17%	Inst Trans	-	Short Ratio	0.82	Perf Half Y	-77.82%
Book/sh	0.30	P/B	0.72	EPS next Y	45.45%	ROA	-45.31%	Short Interest	0.33M	Perf Year	-81.13%
Cash/sh	0.05	P/C	4.16	EPS next 5Y	-	ROE	-61.89%	52W Range	0.22 - 1.68	Perf YTD	-76.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	31.10%	ROI	-84.59%	52W High	-87.20%	Beta	0.64
Dividend TTM	-	Quick Ratio	2.34	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-2.23%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	2.34	EPS Y/Y TTM	63.92%	Oper. Margin	0.00%	RSI (14)	23.93	Volatility	13.20% 11.41%
Employees	-	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.60
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	81.22%	Payout	-	Rel Volume	2.34	Prev Close	0.24
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	May 16 BMO	Avg Volume	409.96K	Price	0.22
SMA20	-28.20%	SMA50	-46.82%	SMA200	-75.02%	Trades		Volume	958,600	Change	-9.92%

Today 07:30AM	FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications (ACCESSWIRE) -9.92%
Jun-04-24 07:30AM	FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication (ACCESSWIRE)
Jun-02-24 03:42PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector week of 6/2/24 (Market Exclusive)
May-31-24 07:30AM	FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest (ACCESSWIRE)
May-28-24 08:00AM	FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication (ACCESSWIRE)
05:15PM	Loading…
May-24-24 05:15PM	FSD Pharma Provides Corporate Update (ACCESSWIRE)
May-20-24 10:53AM	HUGE Stock Earnings: FSD Pharma Reported Results for Q1 2024 (InvestorPlace) +9.72%
May-16-24 08:00AM	FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM) (ACCESSWIRE)
May-07-24 08:30AM	FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia (ACCESSWIRE)
Apr-30-24 08:33AM	FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication (ACCESSWIRE) -6.96%
Apr-25-24 07:47AM	FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM) (ACCESSWIRE)
Apr-22-24 08:00AM	FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM) (ACCESSWIRE)
Apr-17-24 08:00AM	FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products (ACCESSWIRE) -7.80%
Apr-15-24 08:00AM	FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption (ACCESSWIRE) -12.40%
Apr-07-24 10:55PM	FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Newsfile)
10:00PM	Loading…
Apr-01-24 10:00PM	FSD Pharma Announces Filing of Year-End 2023 Results (ACCESSWIRE)
Mar-27-24 08:00AM	FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults (ACCESSWIRE)
Mar-11-24 08:00AM	FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM) (ACCESSWIRE)
Mar-05-24 08:00AM	FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum (ACCESSWIRE)
Feb-28-24 08:00AM	FSD Pharma Announces Debt Settlement (ACCESSWIRE)
Feb-26-24 08:00AM	FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM) (ACCESSWIRE)
Feb-16-24 07:50PM	FSD Pharma Announces US ATM Offering (ACCESSWIRE)
Feb-06-24 07:00AM	Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million (ACCESSWIRE)
Jan-29-24 04:30PM	FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates (ACCESSWIRE)
Jan-16-24 07:30AM	Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot (ACCESSWIRE)
Jan-11-24 01:10PM	GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case (GlobeNewswire) -7.00%
Dec-22-23 07:45PM	FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC (ACCESSWIRE)
Dec-05-23 09:00AM	FSD Pharma Inc. Announces Closing of Private Placement (ACCESSWIRE)
Nov-30-23 08:30AM	FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement (ACCESSWIRE)
Nov-28-23 09:00AM	Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness (ACCESSWIRE) -6.35%
07:30AM	Loading…
Nov-27-23 07:30AM	FSD Pharma Inc. Obtains Final Order for Plan of Arrangement (ACCESSWIRE)
Nov-24-23 07:55AM	Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc. (ACCESSWIRE)
Nov-21-23 09:00AM	FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp. (ACCESSWIRE) +6.30%
Nov-17-23 08:00AM	FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement (ACCESSWIRE)
Nov-15-23 09:00AM	FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023 (ACCESSWIRE) +6.42%
Nov-07-23 11:45AM	FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis (ACCESSWIRE)
Nov-06-23 05:40PM	FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus (ACCESSWIRE)
Oct-23-23 09:00AM	FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu (ACCESSWIRE)
Oct-05-23 07:30AM	FSD Pharma and Celly Nu Enter Into Arrangement Agreement (ACCESSWIRE)
Oct-04-23 08:35AM	FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice (ACCESSWIRE)
Sep-22-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Continued Development of its Exciting New Rapid Detox Drink UNBUZZD, with Video Comments from Kevin Harrington (GlobeNewswire) -8.76%
Sep-18-23 07:30AM	FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated (ACCESSWIRE) +6.67%
Sep-13-23 07:30AM	FSD Pharma Announces Analyst Coverage Initiated by Singular Research (ACCESSWIRE)
Aug-25-23 06:16PM	FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW) (Business Wire) +5.04%
Aug-15-23 07:30AM	FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023 (ACCESSWIRE)
Aug-03-23 06:00AM	InvestmentPitch Media Video Features FSD Pharmas Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink (GlobeNewswire)
Aug-02-23 07:30AM	FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink (ACCESSWIRE)
Jul-17-23 05:00PM	Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201 (Business Wire)
Jul-10-23 07:30AM	FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock (Business Wire)
Jul-04-23 10:00AM	FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors (Business Wire)
Jun-30-23 08:30AM	FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders (Business Wire)
Jun-23-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Granting of Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology to Celly Nutrition (GlobeNewswire) -6.38%
Jun-21-23 07:03AM	DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION (PR Newswire) +6.02%
Jun-20-23 07:30AM	FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology (Business Wire) +11.76%
May-25-23 07:30AM	FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors (Business Wire)
May-16-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement (GlobeNewswire) -8.11%
May-12-23 05:00PM	FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution (Business Wire)
May-11-23 07:30AM	FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari (Business Wire)
May-10-23 07:30AM	FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort (Business Wire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -7.38%
May-08-23 08:50AM	FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 (Business Wire) -6.87%
Apr-17-23 09:00AM	FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis (Business Wire) -5.91%
Apr-12-23 09:01AM	IIROC Trade Resumption - HUGE (PR Newswire) +6.25%
08:32AM	IIROC Trading Halt - HUGE (PR Newswire)
08:30AM	FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023 (Business Wire)
Mar-31-23 08:00PM	FSD Pharma Announces Filing of Year-End 2022 Results (Business Wire)
Mar-30-23 08:30AM	FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors (Business Wire)
Mar-22-23 08:30AM	FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder (Business Wire)
Mar-14-23 08:30AM	FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock (Business Wire)
Mar-01-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Addition of Kevin Harrington, Author, Shark Tank Original, and Infomercial Pioneer to its Advisory Board (GlobeNewswire)
Feb-28-23 08:30AM	Original "Shark" and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board (Business Wire)
Feb-21-23 02:30AM	FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum (Business Wire) +9.70%
Feb-15-23 07:30AM	FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements (Business Wire)
Feb-14-23 02:30AM	FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse (Business Wire)
Feb-09-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS (GlobeNewswire)
Feb-07-23 08:30AM	FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate (Business Wire) +8.20%
Jan-30-23 08:30AM	Recruiting Underway in FSD Pharmas Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) (Business Wire)
Jan-19-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS (GlobeNewswire)
Jan-17-23 08:30AM	FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation (Business Wire)
Jan-13-23 08:30AM	FSD Pharma Announces Share Repurchase Program (Business Wire) +5.46%
Jan-09-23 08:30AM	FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia (Business Wire)
Jan-06-23 08:30AM	FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023 (Business Wire)
Nov-28-22 04:30PM	FSD Pharma Announces Changes to the Board of Directors (Business Wire)
Nov-15-22 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Companys Former CEO, has been Dismissed in its Entirety (GlobeNewswire)
Nov-10-22 09:00AM	FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari (Business Wire)
Sep-29-22 08:30AM	FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Business Wire)
Sep-12-22 08:30AM	FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available (Business Wire)
Sep-06-22 08:30AM	FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Business Wire)
Jul-13-22 08:30AM	FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium (Business Wire)
Jun-27-22 08:30AM	FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates (Business Wire)
Jun-01-22 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Submission of an Investigational New Drug or IND Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder (GlobeNewswire)
May-31-22 08:30AM	FSD Pharma Files Investigational New Drug Application ("IND") with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates (Business Wire)
May-24-22 08:30AM	FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs (Business Wire)
May-11-22 06:00AM	InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million (GlobeNewswire)
May-10-22 03:00AM	FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets (Business Wire)
May-06-22 10:41AM	FSD Pharma Announces Dismissal of Derivative Complaint (Business Wire)
May-02-22 03:30AM	FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates (Business Wire)
Apr-21-22 08:30AM	FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board (Business Wire)
Apr-08-22 08:30AM	FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari (Business Wire)
Apr-06-22 08:30AM	FSD Pharma Issues Corporate Updates (Business Wire)

FSD Pharma, Inc. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUGE

FSD Pharma Inc

Upgrade your FINVIZ experience